Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
India
/
Materials
Create a narrative
Jubilant Ingrevia Community
NSEI:JUBLINGREA Community
3
Narratives
written by author
0
Comments
on narratives written by author
4
Fair Values set
on narratives written by author
Create a narrative
Community Investing Ideas
Jubilant Ingrevia
Popular
Undervalued
Overvalued
Jubilant Ingrevia
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Tightening Environmental Rules Will Erode Specialty Chemicals
Key Takeaways Regulatory pressures and rising demand for greener alternatives threaten profitability and growth across core chemical segments. High revenue concentration and stalled diversification efforts risk greater earnings volatility amid intensifying global competition.
View narrative
₹713.00
FV
0.7% undervalued
intrinsic discount
20.67%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
13 days ago
author updated this narrative
Jubilant Ingrevia
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Green Trends And Bio-Based Chemicals Will Capture Premium Markets
Key Takeaways Ongoing capacity expansion, R&D innovation, and green initiatives position Jubilant Ingrevia for strong margin gains, higher-value revenues, and global market share growth. Premium nutraceutical demand and shifting global sourcing trends boost export-led revenues, sustainable pricing power, and diversification across specialty end-markets.
View narrative
₹1.10k
FV
35.6% undervalued
intrinsic discount
20.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Jubilant Ingrevia
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
International Expansion And New Vitamin B3 Facility Will Boost Presence In High-Value Products
Key Takeaways Specialty Chemicals and Nutrition & Health segments are poised for growth, boosting revenue and margins through high-margin chemicals and vitamin B3 production. Expanded global presence and cost efficiency initiatives aim to diversify revenue streams and enhance overall financial health.
View narrative
₹967.67
FV
26.8% undervalued
intrinsic discount
17.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
Updated
narrative
Your Valuation for
JUBLINGREA
JUBLINGREA
Jubilant Ingrevia
Your Fair Value
₹
Current Price
₹708.30
12.7% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
93b
2015
2018
2021
2024
2025
2027
2030
Revenue ₹93.1b
Earnings ₹6.2b
Advanced
Set Fair Value